



**ASX / Media Release**  
**20<sup>th</sup> February 2014**

## **Next generation delivery platform for OncoSil's radiation treatment for solid tumours**

### **Development program to commence this year**

**SYDNEY, 20<sup>th</sup> February, 2014: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company)** is pleased to announce a development program for a next generation delivery platform for its localised radiation technology for the treatment of solid tumours.

The development program is for a treatment called OncoCal, which is an injectable source of P-32 (radioactive phosphorus). It represents an innovation in the delivery of safer local radiation therapy for solid tumours and will complement OncoSil™, the Company's lead product candidate, currently in development for the treatment of pancreatic cancer.

OncoCal has been developed by OncoSil Medical's Chief Scientific Officer Dr. Peter Knox as part of our ongoing research into new ways to deliver radiation therapy to solid tumours. A new patent has been filed and is currently being prosecuted through the main commercial jurisdictions.

The treatment is injected directly into the tumour, where it emits beta radiation locally for approximately three months. The product differs from OncoSil™ in that when it is injected, it forms an insoluble and immobile salt in combination with interstitial fluid, which remains exactly where it is placed.

It was developed based on the success of the Company's existing technology in the area of localised radiation treatment for cancer, and represents a new modality for the treatment of multiple solid tumours.

The production of OncoCal is expected to use a similar reactor time (to OncoSil™) but is likely to generate more P-32, which would in-turn deliver a cost saving to the company.

More significantly, the volume of material to be utilised in a treatment is expected to be much smaller and processing is expected to be much simpler. The starting material is low cost and is available at pharmacopoeial grade. Once out of the reactor, the material is diluted with phosphate and dispensed, and it is anticipated that this could be carried out by a number of different sub-contractors.

The viscosity of OncoCal is low, which means that medical practitioners using the product may be able to use smaller gauge needles to introduce product. It could also be distributed through the tumour volume more effectively.

Dr. Peter Knox, Chief Scientific Officer at OncoSil Medical Ltd commented:

*"OncoCal represents an exciting innovation in the delivery of safer local radiation therapy for solid tumours, and further highlights our commitment to the therapeutic potential of the isotope phosphorus-32. As an injectable liquid, it has ease of administration while still providing the benefit of local and safer radiation therapy to tumours."*

OncoSil Medical CEO Dr. Neil Frazer said:

*"We are continually looking at ways to expand our portfolio of safer local radiation therapies for tumours, based on the success of our OncoSil™ technology, and we look forward to progressing the development of OncoCal in conjunction with the upcoming clinical trial of OncoSil™ in the year ahead."*

ENDS

Contact:

**Dr Neil Frazer**

**Chief Executive Officer and Managing Director**

[neil.frazer@oncosil.com.au](mailto:neil.frazer@oncosil.com.au)

T +61 2 9223 3344

Twitter: @Dr\_Neil\_Frazer

#### **About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical.

#### **Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.